Legend Biotech Corp is a biopharmaceutical company that was founded in 2014 and is headquartered in Somerset, New Jersey. The company specializes in the development of innovative cell therapies for the treatment of cancer and other serious diseases. Legend Biotech is dedicated to harnessing the power of the immune system through the discovery and advancement of cutting-edge cellular immunotherapy platforms.
Legend Biotech's primary focus is on the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies. CAR-T therapies involve modifying a patient's own T-cells to express receptors that can recognize and attack cancer cells. The company's flagship product is a CAR-T therapy called Cilta-cel, which has shown promising results in clinical trials for the treatment of multiple myeloma, a type of blood cancer. Legend Biotech is committed to advancing the field of cell therapy and developing novel treatments that can transform the lives of patients.
Legend Biotech has achieved significant milestones in its relatively short history. Notably, the company received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for its CAR-T therapy Cilta-cel in 2019. This designation is granted to therapies that demonstrate the potential to provide substantial improvement over existing treatment options for serious or life-threatening conditions. It reflects the recognition of Cilta-cel's promising efficacy and the urgent need for improved therapies in multiple myeloma.
In addition to its achievements in clinical development, Legend Biotech has also made significant strides in expanding its manufacturing capabilities. The company has established state-of-the-art manufacturing facilities to support the production of its cell therapies, ensuring scalability and quality control. This investment in manufacturing infrastructure positions Legend Biotech for potential commercial success as it progresses its therapies through clinical trials and regulatory approval processes.
Legend Biotech continues to focus on research and development to advance its pipeline of potential therapies. The company actively engages in scientific collaborations and partnerships to accelerate innovation in the field of cellular immunotherapy.